CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-11-10): Inotropics, age predict mortality after transplant for acute liver failure

Clinical

Inotropics, age predict mortality after transplant for acute liver failure

Last Updated: 2011-11-10 17:30:12 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A few factors seem to predict mortality in patients who undergo liver transplantation for acute liver failure, a new study has found. But liver dysfunction is not among them.

Older age in donors or recipients, poor renal health, low serum sodium and the use of inotropic drugs were independent risk factors for death within a year after transplant in a study by Dr. Young-Joo Jin at the University of Ulsan College of Medicine in Seoul, South Korea.

Dr. Jin presented the findings November 5 at the annual meeting of the American Association for the Study of Liver Diseases in San Francisco.

Dr. Jin and his team followed 160 patients for a median of 34 months after transplant for acute liver failure. One- and three-year patient survival rates were 78.8% and 74.6%, respectively.

More than three quarters of the patients received grafts from living donors, but whether the donor was living or deceased did not affect either patient or graft survival, the researchers found.

The use of inotropic drugs at the time of transplant was associated with the highest one-year mortality risk (hazard ratio: 4.69; p<0.01). Other independent risk factors for mortality within a year after transplant were older recipient age (HR: 1.03; p=0.08) and older donor age (HR: 1.04; p=0.02).

Higher serum sodium (HR: 0.96; p=0.05) and higher glomerular filtration rate (HR: 0.99; p=0.04) were inversely associated with one-year mortality.

Dr. Patricia Sheiner, director of transplant at Hartford Hospital in Hartford, Connecticut, who was not involved in the study, told Reuters Health this is good-to-know information. "It may be a more formalized way to look at risk," she said in an email.

She called the findings interesting, but "not wildly new or different."

"No paper says exactly the same thing," Dr. Sheiner said. Other studies, she noted, have implicated intubation, encephalopathy, bilirubin, and other factors.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.